ARS Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
I'm PortAI, I can summarize articles.
ARS Pharmaceuticals Inc reported a quarterly adjusted loss of 46 cents per share for the quarter ended June 30, compared to a loss of 13 cents per share in the same quarter last year. Revenue surged 3,043.4% to $15.72 million, exceeding analyst expectations of $13.78 million. The company reported a total loss of $44.88 million. Despite a 4.5% drop in shares this quarter, they have gained 57.9% year-to-date. Analysts maintain a "strong buy" rating, with a median 12-month price target of $30.00, 44.5% above the last closing price of $16.66.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments